50 results about "Isoflavonoid" patented technology

The invention is suitable for the technical field of gene engineering, and provides a soybean MYB transcription factor gene and application thereof in increasing the content of isoflavone. The soybean MYB transcription factor gene is GmMYB3a, and the nucleotide sequence of the soybean MYB transcription factor gene is as shown in SEQ ID NO. 1. According to the invention, a pTF101-GmMYB3a overexpression vector and an RNAi-GmMYB3a interference vector are successfully constructed, and the constructed vectors are transferred into a receptor soybean variety Williams 82. Experimental results show that the soybean strain with overexpression of the GmMYB3a gene shows higher isoflavone content, while the soybean strain with interference of the GmMYB3a gene shows lower isoflavone content, and the positive regulation effect of the GmMYB3a in the isoflavone biosynthesis process is proved. The invention not only provides an innovative molecular breeding strategy for cultivating soybean strains with high isoflavone content, but also has remarkable application potential and market prospect.

The invention discloses a health-care food for delaying ovarian aging, which belongs to the technical field of health-care foods and comprises a composition for improving the levels of anti-mullerian test tube hormone and superoxide dismutase and functional auxiliary materials, the composition for improving the anti-muller test tube hormone and superoxide dismutase level is prepared from the following components in parts by weight: 2 to 5 parts of pyrroloquinoline quinone PQQ, 30 to 80 parts of cranberry powder and 40 to 100 parts of an isoflavone extract, and the content of the pyrroloquinoline quinone PQQ is 2 to 5 parts, the content of the cranberry powder is 30 to 80 parts, and the content of the isoflavone extract is 40 to 100 parts. The pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract in a specific formula have the effect of synergistically improving the levels of anti-muller test tube hormone and superoxide dismutase, and the health food prepared from the pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract can improve sleep, improve urinary tract infection of middle-aged women, delay ovarian aging and the like.

The invention provides a dihydroisoflavone compound, a preparation method and application thereof, a derivative of the dihydroisoflavone compound, application of the derivative and a pharmaceutical composition, and relates to the technical field of medicines. The dihydroisoflavone compound and the derivative thereof provided by the invention have a remarkable inhibition effect on triple-negative breast cancer cells, and the half inhibition concentration value of the dihydroisoflavone compound on the triple-negative breast cancer cells is 0.86 mu M and is equivalent to that of a positive drug paclitaxel; a new choice, a new thought and a technical support are provided for developing the medicine for treating the triple negative breast cancer, and the medicine has important clinical application value.

The present invention discloses a method for separating 6-formylindomyrtone A from a high isoflavone mixture, and the steps are as follows: 1) Using the ophiopogon japonicus high isoflavone mixture as a raw material, dissolving the raw material in a mixed solution composed of ethyl acetate and a hydrophobic organic solvent to obtain a raw material solution; 2) Using a binary mixed solvent composed of an ionic liquid and water as an extractant and using the same solvent as the solvent of the raw material solution as a detergent, performing fractional extraction on the raw material solution, and collecting the raffinate; 3) Subjecting the raffinate to vacuum concentration, washing with water and drying treatment to obtain 6-formylindomyrtone A. The present invention uses an ionic liquid or a binary mixed solvent composed of an ionic liquid and a medium-polarity to polar organic solvent as an extractant, has a high selective separation ability for 6-formylindomyrtone A, and the purity and yield of the separated 6-formylindomyrtone A can both reach more than 90%.

The invention discloses an application of polygonatum cyrtonema cyclase PcAS1 in promoting synthesis of hematoxylin A. The cyclase PcAS1 is derived from polygonatum cyrtonema, a high isoflavone compound hematoxylin A is synthesized in a plant body, and according to the application, a recombinant plant expression vector for expressing a PcAS1 gene is constructed and transformed into the plant to realize synthesis of the hematoxylin A. Based on multiple omics data such as whole genome, re-sequencing and transcriptome of polygonatum cyrtonema, key cyclase PcAS1 closely related to homoisoflavone biosynthesis is systematically mined. Through a tobacco transient expression system and a polygonatum cyrtonema hairy root transformation system, it is proved for the first time that cyclase PcAS1 can significantly promote synthesis of high isoflavone hematoxylon A, and biosynthesis of hematoxylon A is achieved in polygonatum cyrtonema for the first time.

The invention belongs to the field of biological organic fertilizers, and particularly discloses a plant-source insect-expelling and insect-killing organic fertilizer based on fermented soybeans and a preparation method of the plant-source insect-expelling and insect-killing organic fertilizer. Soybean residues are fermented through a compound microbial agent, and natural plant extracts are added to serve as synergistic components. The compound microbial agent comprises strains capable of generating volatile insect repellent compounds and strains capable of promoting soybean nutrition degradation, such as producing bacteria of benzoic acid and isoflavone compounds, photosynthetic bacteria and the like. The natural plant extract is derived from mint, lavender or melia azedarach, so that the parasite expelling effect is enhanced. The preparation method comprises the steps of soybean crushing, inoculant inoculation, illumination fermentation, plant extract addition and the like. The final product is rich in micromolecular nutrient substances and insect-repelling active components, is suitable for planting crops such as tomatoes, and can effectively reduce the use of chemical pesticides and promote the development of green agriculture.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The invention relates to a polymethoxy homoisoflavone derivative or a pharmaceutically acceptable salt thereof, which is characterized in that the structural formula of the derivative is as shown in a general formula (I) or a general formula (II), and the invention also relates to a corresponding pharmaceutical composition and application thereof. The polymethoxy homoisoflavone compound which accords with the general formula and is high in anti-tumor activity is synthesized by the method.

The application relates to application of C-methylated high isoflavone compounds in preparation of antitumor drugs and belongs to the technical field of drug application. In order to solve the problem that the existing antitumor activity is not much reported, the application of C-methylated high isoflavone compounds in preparation of antitumor drugs is provided, the C-methylated high isoflavone compounds are selected from compounds shown in the following formula 1 or formula 2: the C-methylated high isoflavone compounds or pharmaceutically acceptable salts thereof are used as active ingredients for preparation of antitumor drugs for preventing and / or treating adrenal pheochromocytoma (PC-12) and / or human brain astrocytoma (U-87MG). The C-methylated high isoflavone compounds have the advantages of high activity and high inhibition capacity, can be extracted from polygonatum sibiricum and have good drug safety.

The invention provides a method for inhibiting the progress of diabetic retinopathy, and the method specifically comprises the following steps: S1, inhibiting the formation of new vessels: reducing the formation of new vessels through tissue hypoxia caused by an inhibitor; s2, inhibiting the expression of TNF-a by using a high-dose anti-inflammatory drug: reducing the adhesion of retinal leukocytes; s3, improving microcirculation and reducing blood high viscosity, namely enhancing the flexibility of red blood cells through a medicine, reducing the high cohesiveness of the red blood cells, and inhibiting the synthesis and release of platelet aggregation factors; s4, delaying retinopathy by the calcium ion antagonist: inhibiting and removing oxygen free radicals, improving blood rheology and inhibiting platelet aggregation; and S5, improving microcirculation disturbance and retinopathy by using isoflavone substances: inhibiting the occurrence speed of the lesion and relieving symptoms. According to the method for inhibiting the progress of the diabetic retinopathy, the progress of the diabetic retinopathy can be inhibited through reasonable medicine intervention, so that the development of a therapeutic scheme of the diabetic retinopathy is promoted.

The invention discloses a glycosyl transferase combined mutant and application thereof, and aims to solve the problems that the existing wild PlUGT43 and F196Y single-point mutants thereof have narrow substrate spectrums and cannot efficiently catalyze a plurality of isoflavone derivatives with large structural differences to perform C-glycosylation reaction. The glycosyl transferase combination mutant provided by the invention is a protein which simultaneously contains five mutated sites, namely T81S, N186S, L187A, F196Y and S310P, on the basis of a wild PlUGT43 amino acid sequence as shown in SEQ ID NO.3. The glycosyl transferase combination mutant provided by the invention is a protein which is obtained by mutating five sites, namely T81S, N186S, L187A, F196Y and S310P. Compared with a wild type and an F196Y single-site mutant, the combined mutant has the advantages that the catalytic activity on classical substrates such as daidzein is improved, and efficient C-glycosylation on various substrates such as soybean dihydroaglycone, equol and resveratrol which are difficult to catalyze or extremely low in catalytic efficiency is also realized; the application potential of the glycosyl transferase in the aspect of synthesis of diversified natural products is improved.

The invention relates to a probiotic composite product helpful for inhibiting the activity of angiotensin and a preparation method thereof. The probiotic composite product contains lactobacillus plantarum CW006 and radix puerariae powder. Different from the prior art, the lactobacillus plantarum CWO06 added in the formula of the technical scheme can hydrolyze protein through extracellular protease, reduce conversion from angiotensin I to angiotensin II and reduce hydrolysis inactivation of bradykinin, so that the effect of reducing blood pressure is achieved. The radix puerariae powder serving as an active ingredient is rich in isoflavone substances, has an inhibiting effect on a renin-angiotensin system (RAS), and has an effect of assisting in lowering blood pressure.

The application relates to the technical field of fluorescence detection, in particular to a method for detecting the composition of a lithium metal negative electrode, wherein the lithium metal negative electrode is a lithium metal negative electrode after charge-discharge cycle in a lithium battery, and the method comprises the following steps: adopting an isoflavone compound as a fluorescent probe to detect the composition on the surface of the lithium metal negative electrode. Adopting the isoflavone compound as the probe can realize visual observation and quantitative detection of deposited lithium, lithium dendrites, by-products, dead lithium and a solid electrolyte interface film on the surface of the lithium metal negative electrode.

The invention belongs to the technical field of medicines, and particularly relates to an isoflavone compound, a preparation method thereof and application of the isoflavone compound in preparation of a medicine for treating porcine epidemic diarrhea. The isoflavone compound is prepared by the following method: carrying out Friedel-Crafts acylation reaction on substituted phenylacetic acid and resorcinol under the catalytic action of boron trifluoride diethyl etherate to generate an acylated product; reacting DMF (Dimethyl Formamide) with phosphorus pentachloride to generate a Vilsmeier reagent; and carrying out condensation reaction on the acylation product and a Vilsmeier reagent to obtain the compound. In-vitro experiments prove that the isoflavone compound not only has good anti-PEDV (porcine epidemic diarrhea virus) activity, but also can remarkably relieve inflammatory response induced by PEDV. In addition, a fluorescence resonance energy transfer experiment is adopted, and it is verified that the isoflavone compound can inhibit PEDV 3C sample protease activity. The invention provides a candidate medicine for treating porcine epidemic diarrhea, and has important significance on development and innovation of isoflavone compounds.

The application discloses a stem cell exosome-containing composition and application of the stem cell exosome-containing composition in preparation of a medicine with a liver damage treatment effect, and the stem cell exosome-containing composition comprises, by weight, 0.1-0.5 parts of umbilical cord mesenchymal stem cell exosome, 3-6 parts of pueraria extract, 0.2-1 part of honey, 0.06-0.32 parts of compound vitamin, 0.3-0.7 parts of olive oil, 0.08-0.2 parts of starch, 0.03-0.15 parts of glutamic acid, 0.03-0.15 parts of cysteine, 0.03-0.15 parts of glycine, 0.05-0.35 parts of glucuronolactone, 0.05-0.18 parts of sodium carboxymethyl cellulose and 22-37 parts of deionized water. The stem cell exosome can adjust cell apoptosis, growth, multiplication and differentiation pathways through the transcriptome and proteome of a receptor cell, thereby delaying the occurrence and development of liver diseases; the pueraria extract is rich in various flavones and isoflavones, can promote liver cell regeneration, and provides required nutrients for the liver in cooperation with other components, and effectively treats liver damage.

Disclosed herein are pharmaceutical formulations of isoflavonoid and methods of use.

The application discloses a method for catalyzing sodium borohydride to produce hydrogen at low temperature, which is characterized by using natural flavonoids (including flavone, flavonol, isoflavone and the like) as a catalyst, using methanol or a mixture of methanol and water as a reaction solvent, using NaBH4 as a raw material for hydrogen production, and performing alcoholysis of NaBH4 to produce hydrogen. The catalyst used in the application is abundant in source and low in price, can catalyze sodium borohydride to produce hydrogen through alcoholysis at a wide reaction temperature range, has stable catalytic performance, high hydrogen production rate, good catalytic durability and reusability, and has important significance for the application and popularization of sodium borohydride in the field of hydrogen production.

This invention relates to the field of biomedical technology, and more particularly to the application of an isoflavone compound, specifically Corylifol A, in the preparation of drugs for the prevention and / or treatment of inflammatory diseases. When used to prepare drugs for the prevention and / or treatment of inflammatory diseases, this isoflavone compound can directly bind to the IκBα protein and specifically inhibit its phosphorylation, thereby blocking the phosphorylation and nuclear translocation of the NF-κB p65 subunit, ultimately inhibiting the overactivation of the NF-κB signaling pathway. Furthermore, the isoflavone compound can significantly reduce the mortality rate of lipopolysaccharide-induced septicemia in mice, inhibit the levels of inflammatory factors in serum and lung tissue, and effectively alleviate LPS-induced acute lung injury in mice. Simultaneously, when the isoflavone compound is controlled within an effective concentration range, it exhibits no significant cytotoxicity to mouse peritoneal macrophages and can significantly inhibit the production and release of lipopolysaccharide-induced inflammatory factors IL-1β, TNF-α, and IL-6.

Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.

The invention provides a construction method of a characteristic chromatogram of a traditional Chinese medicine compound preparation and a content determination method of seven index components of the traditional Chinese medicine compound preparation. The traditional Chinese medicine compound preparation is a mixture of extracts of radix puerariae, radix pseudostellariae and herba epimedii. The construction method of the specific chromatogram comprises the following steps: preparing a test solution from a traditional Chinese medicine compound preparation to be tested; and performing liquid chromatography detection on the test solution to obtain a characteristic chromatogram of the traditional Chinese medicine compound preparation, the conditions of liquid chromatography detection are as follows: a mobile phase comprises a mobile phase A and a mobile phase B, the mobile phase A is a phosphate solution, and the molar concentration of phosphate contained in the phosphate solution is 10mmol / L-50mmol / L; the mobile phase B is acetonitrile; gradient elution is adopted. The method can realize simultaneous detection of polar saccharide components and weak polar flavone / isoflavone components.

This invention discloses the application of isoflavone compounds in the preparation of antiviral drugs against COVID-19, relating to the field of pharmaceutical formulation technology. The isoflavone compounds are multi-target, dual-function antiviral components, meaning they can target the coronavirus replication target (SARS-CoV-2M)... pro These isoflavones (and / or RdRp) exert direct antiviral effects and can also target p17 inflammatory factors to exert anti-inflammatory effects, thus possessing dual antiviral and anti-inflammatory functions. Given the complex pathophysiology of COVID-19, its treatment should include antiviral infection and regulation of the body's immune-inflammatory system imbalance. Therefore, the aforementioned isoflavone compounds with dual functions are promising candidates for anti-COVID-19 drugs.

The present application provides the use of a flavonoid extract of Polygonatum sibiricum in the preparation of drugs for treating colorectal cancer, and belongs to the field of biomedicine technology. The flavonoid extract of Polygonatum sibiricum and the high-isoflavonoid compounds of the present application exert excellent anti-cancer effects by inhibiting cancer cell proliferation, inducing cancer cell apoptosis and DNA damage. The above-mentioned drugs are highly safe, low-cost, and have good anti-cancer effects. In addition, the high-isoflavonoid compounds can also be used in combination with traditional chemotherapy drugs (such as 5-FU) to exert a synergistic and effective effect, with excellent results. The present application has good clinical application prospects.

The invention discloses a method for accurately quantifying the content of isoflavone components in astragalus membranaceus and application, and belongs to the technical field of isoflavone content detection. The method comprises the following steps: (1) preparing a reference substance solution by taking CG as a reference substance, and obtaining a standard linear equation of the reference substance solution; (2) crushing an astragalus membranaceus sample, and performing ultrasonic extraction and centrifugation to obtain a solution to be detected; (3) performing chromatographic analysis on the to-be-detected solution and the reference substance solution to obtain peak areas; and (4) on the basis of the CG standard linear equation, obtaining a standard linear equation of each isoflavone component to be detected, and then obtaining the content of isoflavone including unstable components CGM and FGM in the sample to be detected according to the peak area of the isoflavone to be detected. According to the method, the contents of six main isoflavone components including unstable components CGM and FGM in the astragalus membranaceus can be detected by using a single reference substance, the method can be used for evaluating the quality of the astragalus membranaceus, and the storage life of the astragalus membranaceus can be detected on the basis of the contents of the CGM and the FGM.

The invention provides an isoflavone compound, a preparation method and application thereof, a derivative of the isoflavone compound, application of the derivative and a pharmaceutical composition, and relates to the technical field of medicines. The isoflavone compound and the derivative thereof provided by the invention have a remarkable inhibition effect on various crop pathogenic fungi, provide a new thought and technical support for preparing an agricultural antibacterial agent, and have important application value. The test result of the embodiment shows that the minimum inhibitory concentrations (MIC) of the isoflavone compound provided by the invention on the physalospora piricola, the strawberry black spot bacteria and the peanut leaf spot bacteria are 6.25 mu g / mL, 12.5 mu g / mL and 12.5 mu g / mL respectively, which indicates that the isoflavone compound provided by the invention has an obvious inhibition effect on the physalospora piricola, the strawberry black spot bacteria and the peanut leaf spot bacteria.

The invention discloses Chinese herbal medicine sappan wood for treating tilapia bacterial meningitis, application and an application method, the Chinese herbal medicine sappan wood effectively becomes brazilin, the brazilin is a homoisoflavone compound, and the molecular formula of the brazilin is C16H14O5. The application includes that the compound has an inhibiting effect on tilapia mossambica source streptococcus agalactiae and can penetrate through a tilapia mossambica blood brain barrier. The application method comprises the steps of soaking treatment, pouring treatment and mixing treatment. The hematoxylon is selected as the medicine for treating the nile tilapia bacterial meningitis for the first time and has the effects of lowering the expression level of inflammatory factors of the nile tilapia bacterial meningitis and improving the survival rate of the nile tilapia, and the Chinese herbal medicine hematoxylon used in the invention is simple in use mode and low in price and has very strong clinical transformation significance.

The invention discloses a preparation method and application of soybean-sourced nano phytoestrogen nano vesicles, belongs to the technical field of biological nano materials, solves the technical problems of poor bone targeting ability and low bioavailability of supplemented exogenous estrogens, and comprises the following steps: S1, weighing, cleaning and soaking; s2, crushing and filtering; s3, performing differential centrifugation; s4, performing extrusion to obtain nano phytoestrogen nano vesicles (SVs) from soybeans, and storing the nano phytoestrogen nano vesicles (SVs) at-80 DEG C for later use; the prepared SVs are applied to preparation of medicines for treating postmenopausal osteoporosis diseases. The soybean-sourced phytoestrogen nano-vesicle prepared by combining a differential centrifugation method with an extrusion method is wide in raw material source and simple in extraction process, is used as a plant estrogen, is rich in various bioactive components such as proteins, lipids and isoflavonoids, reverses the state of bone resorption and bone formation imbalance under the estrogen deficiency state, and has a good application prospect. And a new solution is provided for the treatment of postmenopausal osteoporosis.

The invention relates to the technical field of medicinal chemistry and pharmacotherapeutics, and mainly relates to a carborane-containing isoflavone derivative as well as a preparation method and application thereof. The carborane-containing isoflavone derivative provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof, and also provides a preparation method thereof, the compound shows antitumor activity in related cancer cell lines, overcomes the defect that the active action site and mechanism of the isoflavone compound are not clear, and has a good application prospect. The BNCT nano-material has good targeting property, can realize double functions of BNCT precise positioning treatment and tumor growth and migration inhibition, and has very high clinical application value.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The invention belongs to the field of new application of medicines, and particularly relates to application of 7, 3 ', 4'-Trihydroxyisoflavone in preparation of medicines for treating obesity and related metabolic diseases of the obesity, in particular to application of 7, 3 ', 4'-Trihydroxyisoflavone in preparation of medicines for treating the obesity and the related metabolic diseases of the obesity. According to the present invention, 7, 3 ', 4'-Trihydroxyisoflavone is the natural isoflavone compound, and the molecular docking simulation results show that the compound can effectively bind to the potential active site of the GPCPD1 protein; experiments show that the compound can significantly reduce the liver weight and body weight of fat NAFLD model mice induced by high fat diet, reduce intrahepatic lipid droplet deposition and fat vacuolation degeneration, and improve liver function indexes; meanwhile, insulin resistance and abnormal blood glucose metabolism can be relieved. Therefore, the compound can be used for preparing medicines for preventing, relieving or treating obesity and related metabolic disorders, and has important clinical application value.

The invention discloses application of a cytisine-N-isoflavone derivative in preparation of a medicine for resisting non-small cell lung cancer, and belongs to the technical field of biological medicine. The derivative is a compound CNI3, and the medicine takes the compound CNI3 or a pharmaceutically acceptable solvate thereof as an active ingredient; the dosage form can be selected from tablets, capsules, granules, dripping pills, suspensions, syrups, enteric preparations, gels, suppositories, ointments, emulsions and injections, and the administration route can be selected from oral administration, injection administration, respiratory tract inhalation administration, local administration, sublingual administration and rectal administration. Experiments in combination with in-vivo cell level and in-vitro animal level prove that the compound CNI3 promotes apoptosis of non-small cell lung cancer, exerts activity of resisting non-small cell lung cancer, has no obvious toxic or side effect on normal tissue cells, is good in safety, and has a good clinical application prospect when being used for preparing the medicine for resisting non-small cell lung cancer.